{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:34:55Z","timestamp":1788586495392,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40256-023-00599-0","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T02:02:49Z","timestamp":1690855369000},"page":"519-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-0860","authenticated-orcid":false,"given":"Sneha Annie","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderbir","family":"Padda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Johal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"issue":"19","key":"599_CR1","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","volume":"64","author":"C Chuang","year":"2021","unstructured":"Chuang C, Collibee S, Ashcraft L, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64(19):14142\u201352. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01290.","journal-title":"J Med Chem"},{"issue":"12","key":"599_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2015.01.019.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"599_CR3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-i","volume":"62","author":"AA Geisterfer-Lowrance","year":"1990","unstructured":"Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62(5):999\u20131006. https:\/\/doi.org\/10.1016\/0092-8674(90)90274-i.","journal-title":"Cell"},{"issue":"6","key":"599_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/CIRCRESAHA.110.231670","volume":"108","author":"SP Harris","year":"2011","unstructured":"Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108(6):751\u201364. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.231670.","journal-title":"Circ Res"},{"issue":"5","key":"599_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","volume":"471","author":"JA Spudich","year":"2019","unstructured":"Spudich JA. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Pflugers Arch. 2019;471(5):701\u201317. https:\/\/doi.org\/10.1007\/s00424-019-02259-2.","journal-title":"Pflugers Arch"},{"issue":"4","key":"599_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101552","volume":"48","author":"SA Sebastian","year":"2022","unstructured":"Sebastian SA, Panthangi V, Singh K, et al. Hypertrophic cardiomyopathy: current treatment and future options. Curr Probl Cardiol. 2022;48(4): 101552. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101552.","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"599_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/CIRCGENETICS.109.862128","volume":"2","author":"CY Ho","year":"2009","unstructured":"Ho CY, Carlsen C, Thune JJ, et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2(4):314\u201321. https:\/\/doi.org\/10.1161\/CIRCGENETICS.109.862128.","journal-title":"Circ Cardiovasc Genet"},{"issue":"6","key":"599_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","volume":"13","author":"CY Ho","year":"2020","unstructured":"Ho CY, Olivotto I, Jacoby D, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2020;13(6): e006853. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.006853.","journal-title":"Circ Heart Fail"},{"issue":"25","key":"599_CR9","doi-asserted-by":"publisher","first-page":"e533","DOI":"10.1161\/CIR.0000000000000938","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;142(25):e533\u201357. https:\/\/doi.org\/10.1161\/CIR.0000000000000938.","journal-title":"Circulation"},{"issue":"10253","key":"599_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X.","journal-title":"Lancet"},{"issue":"1","key":"599_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(1):34\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.020.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"599_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nsmb.3408","volume":"24","author":"S Nag","year":"2017","unstructured":"Nag S, Trivedi DV, Sarkar SS, et al. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat Struct Mol Biol. 2017;24(6):525\u201333. https:\/\/doi.org\/10.1038\/nsmb.3408.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"599_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1042\/BST20140324","volume":"43","author":"JA Spudich","year":"2015","unstructured":"Spudich JA. The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy. Biochem Soc Trans. 2015;43(1):64\u201372. https:\/\/doi.org\/10.1042\/BST20140324.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"599_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","volume":"10","author":"DV Trivedi","year":"2018","unstructured":"Trivedi DV, Adhikari AS, Sarkar SS, Ruppel KM, Spudich JA. Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light. Biophys Rev. 2018;10(1):27\u201348. https:\/\/doi.org\/10.1007\/s12551-017-0274-6.","journal-title":"Biophys Rev"},{"issue":"14","key":"599_CR15","doi-asserted-by":"publisher","first-page":"8177","DOI":"10.1073\/pnas.1920632117","volume":"117","author":"E Brunello","year":"2020","unstructured":"Brunello E, Fusi L, Ghisleni A, et al. Myosin filament-based regulation of the dynamics of contraction in heart muscle. Proc Natl Acad Sci USA. 2020;117(14):8177\u201386. https:\/\/doi.org\/10.1073\/pnas.1920632117.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"599_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.121.056324","volume":"144","author":"MJ Daniels","year":"2021","unstructured":"Daniels MJ, Fusi L, Semsarian C, Naidu SS. Myosin modulation in hypertrophic cardiomyopathy and systolic heart failure: getting inside the engine. Circulation. 2021;144(10):759\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056324.","journal-title":"Circulation"},{"issue":"5","key":"599_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148557","volume":"132","author":"SM Day","year":"2022","unstructured":"Day SM, Tardiff JC, Ostap EM. Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure. J Clin Investig. 2022;132(5): e148557. https:\/\/doi.org\/10.1172\/JCI148557.","journal-title":"J Clin Investig"},{"key":"599_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.975076","volume":"13","author":"M Kawana","year":"2022","unstructured":"Kawana M, Spudich JA, Ruppel KM. Hypertrophic cardiomyopathy: mutations to mechanisms to therapies. Front Physiol. 2022;13: 975076. https:\/\/doi.org\/10.3389\/fphys.2022.975076.","journal-title":"Front Physiol"},{"issue":"1","key":"599_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acs.chemrev.9b00264","volume":"120","author":"J Robert-Paganin","year":"2020","unstructured":"Robert-Paganin J, Pylypenko O, Kikuti C, Sweeney HL, Houdusse A. Force generation by myosin motors: a structural perspective. Chem Rev. 2020;120(1):5\u201335. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00264.","journal-title":"Chem Rev"},{"issue":"9","key":"599_CR20","doi-asserted-by":"publisher","first-page":"E1991","DOI":"10.1073\/pnas.1715247115","volume":"115","author":"KH Lee","year":"2018","unstructured":"Lee KH, Sulbar\u00e1n G, Yang S, et al. Interacting-heads motif has been conserved as a mechanism of myosin II inhibition since before the origin of animals. Proc Natl Acad Sci USA. 2018;115(9):E1991\u20132000. https:\/\/doi.org\/10.1073\/pnas.1715247115.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10062","key":"599_CR21","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","volume":"388","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJ, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388(10062):2895\u2013903. https:\/\/doi.org\/10.1016\/S0140-6736(16)32049-9.","journal-title":"Lancet"},{"issue":"2","key":"599_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JC Fang","year":"2021","unstructured":"Fang JC, Filippatos G, Fonseca C, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2025797.","journal-title":"N Engl J Med"},{"issue":"3","key":"599_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2022.11016","volume":"328","author":"GD Lewis","year":"2022","unstructured":"Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA. 2022;328(3):259\u201369. https:\/\/doi.org\/10.1001\/jama.2022.11016.","journal-title":"JAMA"},{"issue":"9","key":"599_CR24","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/ejhf.1933","volume":"22","author":"AA Voors","year":"2020","unstructured":"Voors AA, Tamby JF, Cleland JG, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22(9):1649\u201358. https:\/\/doi.org\/10.1002\/ejhf.1933.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"599_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med. 2019;170(11):741\u20138. https:\/\/doi.org\/10.7326\/M18-3016.","journal-title":"Ann Intern Med"},{"issue":"21","key":"599_CR26","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(21):2649\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"599_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80(2):95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048.","journal-title":"J Am Coll Cardiol"},{"key":"599_CR28","unstructured":"Cytokinetics. Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting. https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-presents-new-data-redwood-hcm-ole-late-breaking-0. Accessed 3 Mar 2023."},{"key":"599_CR29","unstructured":"ClinicalTrials.gov. CY 6031 study will evaluate the effects of treatment with aficamten (CK-3773274) over a 24-week period on cardiopulmonary exercise capacity and health status in patients with symptomatic oHCM (SEQUOIA-HCM) SEQUOIA-HCM. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05186818. Accessed 1 Mar 2023."},{"issue":"8","key":"599_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","volume":"7","author":"FI Malik","year":"2022","unstructured":"Malik FI, Robertson LA, Armas DR, et al. A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. JACC Basic Transl Sci. 2022;7(8):763\u201375. https:\/\/doi.org\/10.1016\/j.jacbts.2022.04.008.","journal-title":"JACC Basic Transl Sci."},{"issue":"9","key":"599_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024656","volume":"11","author":"A Masri","year":"2022","unstructured":"Masri A, Olivotto I. Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter. J Am Heart Assoc. 2022;11(9): e024656. https:\/\/doi.org\/10.1161\/JAHA.121.024656.","journal-title":"J Am Heart Assoc"},{"issue":"9_Supplement","key":"599_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0735-1097(22)01235-9","volume":"79","author":"A Owens","year":"2022","unstructured":"Owens A, Masri A, Abraham T, et al. Efficacy and safety of aficamten and disopyramide coadministration in obstructive hypertrophic cardiomyopathy: results from REDWOOD-HCM cohort 3. J Am Coll Cardiol. 2022;79(9_Supplement):244. https:\/\/doi.org\/10.1016\/S0735-1097(22)01235-9.","journal-title":"J Am Coll Cardiol"},{"key":"599_CR33","unstructured":"Cytokinetics. Cytokinetics Announces Results from Cohort 3 of REDWOOD-HCM Presented at American College of Cardiology 71st Annual Scientific Session. https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-results-cohort-3-redwood-hcm-presented. Accessed 8 May 2023."},{"issue":"8_Supplement","key":"599_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0735-1097(23)01053-7","volume":"81","author":"A Masri","year":"2023","unstructured":"Masri A, Sherrid M, Choudhury L, et al. Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (REDWOOD-HCM cohort 4). J Am Coll Cardiol. 2023;81(8_Supplement):609. https:\/\/doi.org\/10.1016\/S0735-1097(23)01053-7.","journal-title":"J Am Coll Cardiol"},{"key":"599_CR35","unstructured":"Cytokinetics. Cytokinetics presents positive results from cohort 4 of REDWOOD-HCM and long-term results from FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session. https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-presents-positive-results-cohort-4-redwood-hcm-and. Accessed 8 May 2023."},{"issue":"8","key":"599_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0735-1097(23)00768-4","volume":"81","author":"S Saberi","year":"2023","unstructured":"Saberi S, Abraham T, Choudhury L, et al. Long-term efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81(8):324. https:\/\/doi.org\/10.1016\/S0735-1097(23)00768-4.","journal-title":"J Am Coll Cardiol"},{"key":"599_CR37","unstructured":"Saberi S., Abraham T, Choudhury L, et al. FOREST-HCM investigators. Long-term efficacy and safety of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. https:\/\/cytokinetics.com\/wp-content\/uploads\/2023\/03\/ACC23-FOREST-HCM-Poster-FINAL-V2.pdf. Accessed 9 May 2023."},{"key":"599_CR38","unstructured":"ClinicalTrials.gov. CY 6022 is an Open Label Study to Collect Long-term Safety and Tolerability Data for Aficamten (CK-3773274) (FOREST-HCM). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04848506. Accessed 4 Mar 2023."},{"key":"599_CR39","unstructured":"Cytokinetics. Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy. https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-start-sequoia-hcm-phase-3-clinical-trial. Accessed 3 Mar 2023."},{"key":"599_CR40","unstructured":"Cytokinetics. Cytokinetics Announces Receipt of Breakthrough Therapy Designation from FDA for Aficamten. https:\/\/ir.cytokinetics.com\/news-releases\/news-release-details\/cytokinetics-announces-receipt-breakthrough-therapy-designation. Accessed 4 Mar 2023."},{"issue":"1","key":"599_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/ijms21010226","volume":"21","author":"O Tsukamoto","year":"2019","unstructured":"Tsukamoto O. Direct sarcomere modulators are promising new treatments for cardiomyopathies. Int J Mol Sci. 2019;21(1):226. https:\/\/doi.org\/10.3390\/ijms21010226.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"599_CR42","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Mavacamten: first approval. Drugs. 2022;82(10):1127\u201335. https:\/\/doi.org\/10.1007\/s40265-022-01739-7.","journal-title":"Drugs"},{"issue":"6","key":"599_CR43","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49(6):718\u201333. https:\/\/doi.org\/10.1080\/00498254.2018.1495856.","journal-title":"Xenobiotica"},{"key":"599_CR44","unstructured":"MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb. CAMZYOSTM (mavacamten): US prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214998s000lbl.pdf. Accessed 4 Mar 2023."},{"key":"599_CR45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63703","volume":"10","author":"N Suman","year":"2021","unstructured":"Suman N, Darshan VT. To lie or not to lie: super-relaxing with myosins. Elife. 2021;10: e63703. https:\/\/doi.org\/10.7554\/eLife.63703.","journal-title":"Elife"},{"issue":"4","key":"599_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40119-022-00283-5","volume":"11","author":"E Packard","year":"2022","unstructured":"Packard E, de Feria A, Peshin S, Reza N, Owens AT. Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy. Cardiol Ther. 2022;11(4):491\u2013507. https:\/\/doi.org\/10.1007\/s40119-022-00283-5.","journal-title":"Cardiol Ther."},{"key":"599_CR47","unstructured":"ClinicalTrials.gov. A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Obstructive Hypertrophic Cardiomyopathy. NCT05556343. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05556343. Accessed 3 Mar 2023."},{"key":"599_CR48","unstructured":"BioSpace. MyoKardia Begins Dosing in Phase 1 Clinical Study of MYK-224 for Hypertrophic Cardiomyopathy. Aug 21, 2019. https:\/\/www.biospace.com\/article\/myokardia-begins-dosing-in-phase-1-clinical-study-of-myk-224-for-hypertrophic-cardiomyopathy\/. Accessed 3 Mar 2023."},{"issue":"2_Supplement","key":"599_CR49","doi-asserted-by":"publisher","first-page":"ehaa946.3713","DOI":"10.1093\/ehjci\/ehaa946.3713","volume":"41","author":"BS Ferguson","year":"2020","unstructured":"Ferguson BS, Stern JA, Oldach MS, et al. Acute effects of a mavacamten-like myosin-inhibitor (MYK-581 in a feline model of obstructed hypertrophic cardiomyopathy: evidence of improved ventricular filling (beyond obstruction reprieve). Eur Heart J. 2020;41(2_Supplement):ehaa946.3713. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3713.","journal-title":"Eur Heart J"},{"key":"599_CR50","unstructured":"ClinicalTrials.gov. Efficacy and Safety of Aficamten (CK-3773274) Compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction (MAPLE-HCM). Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05767346. Accessed 9 May 2023."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00599-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00599-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00599-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:27:57Z","timestamp":1693200477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00599-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00599-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]},"assertion":[{"value":"19 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors Sneha Annie Sebastian, Inderbir Padda, Eric J Lehr, and Gurpreet Johal declare that we have no conflict of interest. Also, the authors declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available within the article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SAS: conceptualization, methodology, investigation, data curation, writing\u2014original draft, writing\u2014review and editing. IP: writing\u2014original draft. EJL: writing\u2014review and editing. GJ: writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}